1-methyl-1H-pyrrole-2-ethylamine → 7-[(4-fluorophenyl)methyl]-4-hydroxy-1-methyl-N-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide
반응식
[F:1][C:2]1[CH:7]=[CH:6][C:5]([CH2:8][C:9]2[CH:18]=[C:17]3[C:12]([C:13]([OH:26])=[C:14]([C:21]([O:23]CC)=O)[C:15](=[O:20])[N:16]3[CH3:19])=[N:11][CH:10]=2)=[CH:4][CH:3]=1.[CH3:27][N:28]1[CH:32]=[CH:31][CH:30]=[C:29]1[CH2:33][CH2:34][NH2:35]>>[F:1][C:2]1[CH:7]=[CH:6][C:5]([CH2:8][C:9]2[CH:18]=[C:17]3[C:12]([C:13]([OH:26])=[C:14]([C:21]([NH:35][CH2:34][CH2:33][C:29]4[N:28]([CH3:27])[CH:32]=[CH:31][CH:30]=4)=[O:23])[C:15](=[O:20])[N:16]3[CH3:19])=[N:11][CH:10]=2)=[CH:4][CH:3]=1참가 물질
3
반응물 2
생성물 1
실험 절차
In a similar manner to that described in example 196, from ethyl 7-[(4-fluorophenyl)methyl]-4-hydroxy-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxylate (13 mg, 0.0365 mmol) described in example 92 and [2-(1-methyl-1H-pyrrol-2-yl)ethyl]amine (45 mg, 0.364 mmol), was prepared 7-[(4-fluorophenyl)methyl]-4-hydroxy-1-methyl-N-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide (13 mg, 86% yield) as a white solid after purification by reverse phase HPLC. 1H NMR (CDCl3) δ 10.31 (br s, 1 H), 8.56 (s, 1 H), 7.38 (s, 1 H), 7.17-7.13 (m, 2 H), 7.04-6.99 (m, 2 H), 6.56 (m, 1 H), 6.06 (m, 1 H), 5.99 (s, 1 H), 4.12 (s, 2 H), 3.68 (m, 2 H), 3.59 (s, 3 H), 3.57 (s, 3 H), 2.90 (m, 2 H); MS m/z 435 (M+1).